State the surprising number first: Eli Lilly's reported revenue was $65.2 billion for full-year 2025. Two years earlier, in 2023, it was $34.1 billion. The 2024 figure sat in between at $45.0 billion. These are not estimates — they are the structured XBRL facts the company tagged in its own SEC filings, the FY2025 10-K filed February 12, 2026 and the FY2024 10-K.
By the numbers, that is a roughly 91% increase in total revenue across two years. For a company already among the largest in pharma at the start of the period, that pace of growth is extraordinary; mature drugmakers typically grow in the single digits. The data shows a clearer story than any narrative: something step-changed Lilly's top line, and the timing maps precisely onto the ramp of its incretin medicines.
The quarterly cadence reinforces it. Lilly's most recent quarterly report, the first-quarter 2026 10-Q, tagged $19.8 billion of revenue for the three months ended March 31, 2026, versus $12.7 billion in the comparable quarter a year earlier — a roughly 56% year-over-year increase in a single quarter. Three consecutive annual figures and a fresh quarter all point the same way.
One discipline matters here: the revenue line is company-wide, not the incretin franchise alone. Lilly sells oncology, immunology, and diabetes products beyond GLP-1s. So the precise claim the filings support is that total revenue nearly doubled in the incretin era — not that GLP-1s alone account for every dollar of growth. Correlation in timing is strong; the filing does not invite us to assert that the franchise is the sole cause.
These figures are retrievable because the EdgarBeast evidence index normalizes the XBRL tags companies embed in their filings, so the same us-gaap:Revenues concept can be compared period over period straight from the source documents. That is what lets a reader verify a doubling rather than take it on faith.
The takeaway, stated plainly and sourced: in two years, one of the world's largest drugmakers nearly doubled its revenue, and every figure in that sentence is in its SEC filings. Whatever you think the GLP-1 era will mean for medicine, the financial scale of it is no longer speculative — it is reported.